6Sonia Napravnik
4Stephen J. Gange
4Keri N. Althoff
3Benigno Rodriguez
Learn More
BACKGROUND The optimal time for the initiation of antiretroviral therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection is uncertain. METHODS We conducted two parallel analyses involving a total of 17,517 asymptomatic patients with HIV infection in the United States and Canada who received medical care during the period from(More)
  • Hasina Samji, Angela Cescon, Robert S. Hogg, Sharada P. Modur, Keri N. Althoff, Kate Buchacz +20 others
  • 2013
BACKGROUND Combination antiretroviral therapy (ART) has significantly increased survival among HIV-positive adults in the United States (U.S.) and Canada, but gains in life expectancy for this region have not been well characterized. We aim to estimate temporal changes in life expectancy among HIV-positive adults on ART from 2000-2007 in the U.S. and(More)
  • Keri N Althoff, Kelly A Gebo, Stephen J Gange, Marina B Klein, John T Brooks, Robert S Hogg +23 others
  • 2010
We assessed CD4 count at initial presentation for HIV care among ≥50-year-olds from 1997-2007 in 13 US and Canadian clinical cohorts and compared to <50-year-olds. 44,491 HIV-infected individuals in the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) were included in our study. Trends in mean CD4 count (measured as cells/mm³) and(More)
Since 2005 we have been developing and implementing an electronic medical record (EMR) that supports both individual and population health care of HIV-infected patients in Haiti. Unreliable electrical power and network infrastructure, cultural differences, variable levels of experience and computer literacy, and the geographic dispersion of the team remain(More)
  • David B. Hanna, Kate Buchacz, Kelly A. Gebo, Nancy A. Hessol, Michael A. Horberg, Lisa P. Jacobson +17 others
  • 2013
BACKGROUND U.S. state AIDS Drug Assistance Programs (ADAPs) are federally funded to provide antiretroviral therapy (ART) as the payer of last resort to eligible persons with HIV infection. States differ regarding their financial contributions to and ways of implementing these programs, and it remains unclear how this interstate variability affects HIV(More)
  • Peter F. Rebeiro, Stephen J. Gange, Michael A. Horberg, Alison G. Abraham, Sonia Napravnik, Hasina Samji +7 others
  • 2016
OBJECTIVE To understand geographic variations in clinical retention, a central component of the HIV care continuum and key to improving individual- and population-level HIV outcomes. DESIGN We evaluated retention by US region in a retrospective observational study. METHODS Adults receiving care from 2000-2010 in 12 clinical cohorts of the North American(More)
  • Luisa Duran, Carla Rodriguez, Dan Drozd, Robin M. Nance, J. A. Chris Delaney, Greer Burkholder +10 others
  • 2015
Fructosamine is an alternative method to hemoglobin A1c (HbA1c) for determining average glycemia. However, its use has not been extensively evaluated in persons living with HIV (PLWH). We examined the relationship between HbA1c and fructosamine values, specifically focusing on anemia (which can affect HbA1c) and albumin as a marker of liver disease. We(More)
The burden of HIV disease has shifted from traditional AIDS-defining illnesses to serious non-AIDS-defining comorbid conditions. Research aimed at improving HIV-related comorbid disease outcomes requires well-defined, verified clinical endpoints. We developed methods to ascertain and verify end-stage renal disease (ESRD) and end-stage liver disease (ESLD)(More)
Access to multi-site clinical data regarding treatment and outcomes of HIV-infected patients in routine care is required to support clinical research to improve the treatment of HIV. As part of the NIAID-funded CFAR Network of Integrated Clinical Systems (CNICS), we have developed a relational XML Schema to extend the existing observational research(More)
  • 1